Selective MRGPRX2 Antagonists for Mast Cell Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mast cell-driven pathologies such as urticaria, atopic dermatitis, and inflammatory bowel disease lack selective inhibitors of MRGPRX2, leading to inadequate control of symptoms like pain, swelling, and inflammation.
Innovation Solution
Development of compounds according to Formula (I) or their pharmaceutically acceptable salts, which act as selective antagonists of MRGPRX2, inhibiting IgE-independent mast cell degranulation and thereby addressing the underlying causes of these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for mast cell-driven pathologies are used, then general symptom management is provided, but selective inhibition of MRGPRX2 is lacking leading to inadequate control of symptoms
Solution Approach 1:
The patent segments the mast cell activation pathway by targeting a specific receptor (MRGPRX2) rather than general mast cell degranulation. The compounds are designed to selectively bind to and inhibit MRGPRX2, separating this specific pathway from other mast cell activation mechanisms, thereby achieving precise symptom control while maintaining overall treatment reliability
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular structures (Formula I with defined substituents R1-R14) that are optimized to interact with the specific binding pocket of MRGPRX2. This localized molecular design ensures high selectivity for the target receptor while maintaining effective inhibition of the pathological pathway
2Measurement precision
If selective MRGPRX2 antagonists are developed, then precise inhibition of IgE-independent mast cell degranulation is achieved, but treatment complexity increases
Solution Approach 1:
The patent utilizes parameter changes by systematically varying molecular parameters in Formula I (substituents R1-R14, ring structures, chain lengths) to optimize both selectivity and simplicity. By adjusting these chemical parameters, the invention achieves high target specificity while maintaining reasonable structural complexity for drug development
Solution Approach 2:
The invention incorporates dynamic elements through the flexible substituent groups in Formula I that can adapt to the MRGPRX2 binding site. The compounds can dynamically interact with the receptor through various bonding modes, enhancing specificity without requiring overly complex rigid structures
Data Source
AI summary
This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.